319 related articles for article (PubMed ID: 19166228)
21. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
Fu X; Nakamori M; Tao L; Amato R; Zhang X
Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
[TBL] [Abstract][Full Text] [Related]
24. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
25. A novel HSV-1 virus, JS1/34.5-/47-, purges contaminating breast cancer cells from bone marrow.
Hu JC; Booth MJ; Tripuraneni G; Davies D; Zaidi SA; Tamburo de Bella M; Slade MJ; Marley SB; Gordon MY; Coffin RS; Coombes RC; Kamalati T
Clin Cancer Res; 2006 Nov; 12(22):6853-62. PubMed ID: 17121907
[TBL] [Abstract][Full Text] [Related]
26. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
27. Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the development of oncolytic HSV-1 vectors: 'arming' of HSV-1 vectors and application of bacterial artificial chromosome technology for their construction.
Jeyaretna DS; Kuroda T
Curr Opin Mol Ther; 2007 Oct; 9(5):447-66. PubMed ID: 17932809
[TBL] [Abstract][Full Text] [Related]
29. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.
Veerapong J; Bickenbach KA; Shao MY; Smith KD; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2007 Sep; 67(17):8301-6. PubMed ID: 17804745
[TBL] [Abstract][Full Text] [Related]
30. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
31. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
Menotti L; Avitabile E
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167582
[TBL] [Abstract][Full Text] [Related]
32. Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.
Smith KD; Shao MY; Posner MC; Weichselbaum RR
Future Oncol; 2007 Oct; 3(5):545-56. PubMed ID: 17927520
[TBL] [Abstract][Full Text] [Related]
33. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
34. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
Mahller YY; Rangwala F; Ratner N; Cripe TP
Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
[TBL] [Abstract][Full Text] [Related]
35. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.
Li H; Dutuor A; Tao L; Fu X; Zhang X
Clin Cancer Res; 2007 Jan; 13(1):316-22. PubMed ID: 17200370
[TBL] [Abstract][Full Text] [Related]
36. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
[TBL] [Abstract][Full Text] [Related]
37. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
Kohno S; Luo C; Goshima F; Nishiyama Y; Sata T; Ono Y
Urology; 2005 Nov; 66(5):1116-21. PubMed ID: 16286150
[TBL] [Abstract][Full Text] [Related]
38. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
40. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]